<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345669</url>
  </required_header>
  <id_info>
    <org_study_id>1200.131</org_study_id>
    <secondary_id>2011-000392-14</secondary_id>
    <nct_id>NCT01345669</nct_id>
  </id_info>
  <brief_title>LUX-Head&amp;Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This randomised, double-blind phase III trial will be performed in patients with head and
      neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy
      and safety of afatinib (BIBW 2992) with placebo as adjuvant therapy to patients who have
      received definitive chemo-radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 17, 2011</start_date>
  <completion_date type="Actual">September 12, 2016</completion_date>
  <primary_completion_date type="Actual">September 12, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Disease Free Survival defined as the time from randomisation until documented tumour recurrence/ second primary tumour (SPT) or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) Rate at 2 Years</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Disease Free Survival (DFS) rate at 2 years. Probability of being disease free at 2 years in percentage is provided based on Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patient Deaths (Overall Survival (OS))</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Overall survival (OS), defined as the time from randomisation until death (regardless of cause). Due to the small event rate in both treatment arms caused by the early termination of the trial, the hazard estimate is not interpretable. Hence presented the total randomized and the percentage of patients died.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Improved Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Improvement was defined as a score that improved from baseline by at least 10 points (on the 0-100 point scale) at any time during the study. If a patient had not improved, worsening was defined as a 10-point worsening at any time during the study. Patients who had neither improved nor worsened were considered as stable. Percentages of patients with improvement in HRQoL are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Time to deterioration was defined as the time from randomisation to the first 10-point worsening on the 0-100 point scale. Patients with no deterioration (including those with disease recurrence/SPT) were censored at the last available HRQoL assessment date. Patients with no post-baseline assessments were censored on the day of randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQOL) Scores Over Time</measure>
    <time_frame>Baseline and 5 years</time_frame>
    <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Scoring of the symptom scales/items followed the European Organisation for Research and Treatment of Cancer (EORTC) scoring manual and a linear transformation of the scores to a 0-100 point scale. Higher values are better.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Afatinib (BIBW 2992)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Afatinib (BIBW 2992)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Histologically or cytologically confirmed loco-regionally advanced head and neck
             squamous cell carcinoma (HNSCC), stage III to IVb

          2. Unresected tumour prior to chemo-radiotherapy (CRT)

          3. Concomitant CRT completed prior to randomisation

          4. After concomitant platinum-based CRT, no evidence of disease (NED) on clinical and
             radiographic examinations

          5. Eastern cooperative oncology group (ECOG) performance status 0 or 1

        Exclusion criteria:

          1. Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules,
             EGFR-targeted antibodies, and/or any investigational agents for HNSCC

          2. Patients with smoking history of less than or equal to 10 pack years and with primary
             tumour site of base of tongue and/or tonsil

          3. Any other malignancy (except for simultaneous HNSCC primaries, appropriately treated
             superficial basal cell skin cancer and surgically cured cervical cancer in situ)
             unless free of disease for at least five years

          4. Known pre-existing Interstitial Lung Disease (ILD)

          5. Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.131.00171 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00181 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00177 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00185 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00173 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00176 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00182 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00175 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00179 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00188 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.10200 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00172 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00184 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00198 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00183 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05451 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Bs As</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05457 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05458 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05452 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05453 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villa Dominico</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.06151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wooloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04353 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04357 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04355 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04351 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04359 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03259 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03256 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03255 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03253 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03252 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03254 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03258 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05554 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barretos</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05555 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jau</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05557 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05553 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05551 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05556 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05652 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vina De Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05651 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vina del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04254 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04253 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04251 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04551 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København Ø</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.2052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35851 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03353 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03362 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03359 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nice cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03365 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orléans Cedex 2</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03355 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03367 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03370 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03354 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03369 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03366 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salouel</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03356 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03357 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04954 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04961 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04953 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04956 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04959 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04951 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04957 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04964 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04963 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04962 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chaidari</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03651 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03652 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03656 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budpest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03654 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03655 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09178 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmadabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09165 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bikaner</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09163 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09173 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09179 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09170 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09180 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09172 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09176 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karamsad,Anand, Gujarat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09162 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madurai, Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09175 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mazagaon, Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09164 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.09159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vishakapatnam</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.97251 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.97253 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03957 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Confreria (CN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03951 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03955 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03960 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08156 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiba, Kashiwa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08161 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Akashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08157 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyogo, Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08159 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanagawa, Isehara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08164 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miyagi, Natori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08160 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Sunto-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tochigi, Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08163 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Koto-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.08154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tokyo, Meguro-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.05252 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35155 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35154 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35153 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.35152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Évora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00759 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00753 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00760 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00761 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00763 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00755 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.00762 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03451 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03454 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03463 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03452 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03459 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03457 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03464 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03465 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03456 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03462 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03455 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03460 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo De Alarcón, Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03466 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03458 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03461 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ávila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04652 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04651 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04151 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04152 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03854 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.03851 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04456 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denbighshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04455 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04459 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04460 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04453 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04451 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04452 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04454 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04458 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.131.04457 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Whitchurch, Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>September 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2017</results_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was a randomised, placebo-controlled, double-blind, parallel arms, multinational phase III trial in which patients were randomised 2:1 to Afatinib or Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afatinib (BIBW 2992)</title>
          <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Primary tumour recurrence</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second primary tumour</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
      <group_list>
        <group group_id="B1">
          <title>Afatinib (BIBW 2992)</title>
          <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="411"/>
            <count group_id="B2" value="206"/>
            <count group_id="B3" value="617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="8.23"/>
                    <measurement group_id="B2" value="57.3" spread="8.64"/>
                    <measurement group_id="B3" value="58.0" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS)</title>
        <description>Disease Free Survival defined as the time from randomisation until documented tumour recurrence/ second primary tumour (SPT) or death from any cause, whichever occurred first.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS)</title>
          <description>Disease Free Survival defined as the time from randomisation until documented tumour recurrence/ second primary tumour (SPT) or death from any cause, whichever occurred first.</description>
          <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.40" lower_limit="16.82">Non calculable because the 75th percentile hasn't been reached</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="16.69">Non calculable because the median hasn't been reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DFS was analysed using a stratified log-rank test with nodal status (N0- N2a vs. N2b-N3) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1) being the stratification factors.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4806</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.569</ci_upper_limit>
            <estimate_desc>Hazard ratio (Afatinib vs. Placebo) from Cox proportional hazards model stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival (DFS) Rate at 2 Years</title>
        <description>Disease Free Survival (DFS) rate at 2 years. Probability of being disease free at 2 years in percentage is provided based on Kaplan-Meier method.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Randomised Set, the number of patients from the randomized set those are disease free (or DFS) at 2 years.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Rate at 2 Years</title>
          <description>Disease Free Survival (DFS) rate at 2 years. Probability of being disease free at 2 years in percentage is provided based on Kaplan-Meier method.</description>
          <population>Randomised Set, the number of patients from the randomized set those are disease free (or DFS) at 2 years.</population>
          <units>Probability (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" lower_limit="61.2" upper_limit="72.5"/>
                    <measurement group_id="O2" value="73.5" lower_limit="66.0" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier (KM) curves were calculated for each treatment group, separately, and the estimates of DFS probabilities from the curves and 95% Confidence interval (CI) (using the Greenwood standard error estimate) were tabulated</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1610</p_value>
            <method>Log Rank</method>
            <param_type>Difference in Kaplan-Meier estimates</param_type>
            <param_value>-6.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.04</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
            <estimate_desc>Difference in Kaplan-Meier estimates of Afatinib vs. Placebo is provided.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patient Deaths (Overall Survival (OS))</title>
        <description>Overall survival (OS), defined as the time from randomisation until death (regardless of cause). Due to the small event rate in both treatment arms caused by the early termination of the trial, the hazard estimate is not interpretable. Hence presented the total randomized and the percentage of patients died.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patient Deaths (Overall Survival (OS))</title>
          <description>Overall survival (OS), defined as the time from randomisation until death (regardless of cause). Due to the small event rate in both treatment arms caused by the early termination of the trial, the hazard estimate is not interpretable. Hence presented the total randomized and the percentage of patients died.</description>
          <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="16.82"/>
                    <measurement group_id="O2" value="11.2" lower_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio from Cox proportional hazards model stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1301</p_value>
            <p_value_desc>p−value (two−sided) from log−rank test stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.444</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.895</ci_lower_limit>
            <ci_upper_limit>2.332</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Improved Health Related Quality of Life (HRQOL)</title>
        <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Improvement was defined as a score that improved from baseline by at least 10 points (on the 0-100 point scale) at any time during the study. If a patient had not improved, worsening was defined as a 10-point worsening at any time during the study. Patients who had neither improved nor worsened were considered as stable. Percentages of patients with improvement in HRQoL are presented.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Improved Health Related Quality of Life (HRQOL)</title>
          <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Improvement was defined as a score that improved from baseline by at least 10 points (on the 0-100 point scale) at any time during the study. If a patient had not improved, worsening was defined as a 10-point worsening at any time during the study. Patients who had neither improved nor worsened were considered as stable. Percentages of patients with improvement in HRQoL are presented.</description>
          <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swallowing (Q5−Q8 from QLQ−HN35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" lower_limit="16.82"/>
                    <measurement group_id="O2" value="27.2" lower_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HN35 (Q1−Q4 from QLQ−HN35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL(Q29−Q30 from QLQ−C30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6"/>
                    <measurement group_id="O2" value="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio and p−value from logistic regression analysis of ’improved vs. not improved’ stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3) for Swallowing (Q5−Q8 from QLQ−HN35).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0561</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.431</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.991</ci_lower_limit>
            <ci_upper_limit>2.068</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio and p−value from logistic regression analysis of ’improved vs. not improved’ stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3) for Pain HN35 (Q1−Q4 from QLQ−HN35).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0523</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.446</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.996</ci_lower_limit>
            <ci_upper_limit>2.098</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds ratio and p−value from logistic regression analysis of ’improved vs. not improved’ stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3) for Global health status/QoL(Q29−Q30 from QLQ−C30).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2570</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.577</ci_lower_limit>
            <ci_upper_limit>1.158</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Deterioration in Health Related Quality of Life (HRQOL)</title>
        <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Time to deterioration was defined as the time from randomisation to the first 10-point worsening on the 0-100 point scale. Patients with no deterioration (including those with disease recurrence/SPT) were censored at the last available HRQoL assessment date. Patients with no post-baseline assessments were censored on the day of randomisation.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Deterioration in Health Related Quality of Life (HRQOL)</title>
          <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Time to deterioration was defined as the time from randomisation to the first 10-point worsening on the 0-100 point scale. Patients with no deterioration (including those with disease recurrence/SPT) were censored at the last available HRQoL assessment date. Patients with no post-baseline assessments were censored on the day of randomisation.</description>
          <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swallowing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.43" lower_limit="3.68">Non calculable because the 75th percentile hasn't been reached</measurement>
                    <measurement group_id="O2" value="31.44" lower_limit="3.78">Non calculable because the 75th percentile hasn't been reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HN35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.06" lower_limit="1.91">Non calculable because the 75th percentile hasn't been reached</measurement>
                    <measurement group_id="O2" value="31.08" lower_limit="3.78">Non calculable because the 75th percentile hasn't been reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.59" lower_limit="1.87">Non calculable because the 75th percentile hasn't been reached</measurement>
                    <measurement group_id="O2" value="25.79" lower_limit="6.21">Non calculable because the 75th percentile hasn't been reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For swallowing scale; Hazard ratio from Cox proportional hazard model stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0591</p_value>
            <p_value_desc>P−value from log−rank test stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.295</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.986</ci_lower_limit>
            <ci_upper_limit>1.700</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For pain HN35 scale; Hazard ratio from Cox proportional hazard model stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <p_value_desc>P−value from log−rank test stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.456</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.113</ci_lower_limit>
            <ci_upper_limit>1.905</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For global health status/QoL scale; Hazard ratio from Cox proportional hazard model stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P−value from log−rank test stratified by baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.604</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.238</ci_lower_limit>
            <ci_upper_limit>2.079</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life (HRQOL) Scores Over Time</title>
        <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Scoring of the symptom scales/items followed the European Organisation for Research and Treatment of Cancer (EORTC) scoring manual and a linear transformation of the scores to a 0-100 point scale. Higher values are better.</description>
        <time_frame>Baseline and 5 years</time_frame>
        <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib (BIBW 2992)</title>
            <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life (HRQOL) Scores Over Time</title>
          <description>HRQoL questionnaires focused on 3 scales: Pain scale from H&amp;N35, Swallowing scale from H&amp;N35 and Global health status/QoL scale from C30. Scoring of the symptom scales/items followed the European Organisation for Research and Treatment of Cancer (EORTC) scoring manual and a linear transformation of the scores to a 0-100 point scale. Higher values are better.</description>
          <population>Randomised Set (RS): Included all patients who were randomised, regardless of taking investigational treatment (as randomised)</population>
          <units>Unit on Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Swallowing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="1.00" lower_limit="3.68"/>
                    <measurement group_id="O2" value="8.8" spread="1.12" lower_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain HN35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="0.98" lower_limit="1.91"/>
                    <measurement group_id="O2" value="9.9" spread="1.10" lower_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global health status/QoL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="2.23" lower_limit="1.87"/>
                    <measurement group_id="O2" value="33.0" spread="2.28" lower_limit="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Scores (swallowing scale) over time were assessed using longitudinal mixed-effects growth curve models with the average profile over time for each endpoint described by a piecewise linear model adjusted for the fixed effects baseline ECOG performance score and nodal status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2232</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Degrees of freedom calculated using the Kenward-Roger method.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
            <estimate_desc>Afatinib minus Placebo mean adjusted for total with data for baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Scores (pain scale) over time were assessed using longitudinal mixed-effects growth curve models with the average profile over time for each endpoint described by a piecewise linear model adjusted for the fixed effects baseline ECOG performance score and nodal status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0028</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Degrees of freedom calculated using the Kenward-Roger method.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
            <estimate_desc>Afatinib minus Placebo mean adjusted for total with data for baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Scores (global health/QoL) over time were assessed using longitudinal mixed-effects growth curve models with the average profile over time for each endpoint described by a piecewise linear model adjusted for the fixed effects baseline ECOG performance score and nodal status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Degrees of freedom calculated using the Kenward-Roger method.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.33</ci_lower_limit>
            <ci_upper_limit>-1.49</ci_upper_limit>
            <estimate_desc>Afatinib minus Placebo mean adjusted for total with data for baseline ECOG (0 or 1) and nodal status (N0−N2a or N2b−N3).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 4 weeks after the last drug administration, up to 84 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afatinib (BIBW 2992)</title>
          <description>Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patient received placebo matching Afatinib film-coated tablets with matching Afatinib dosage regimen, orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Disease recurrence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Groin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Osteoradionecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Radiation fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Radiation necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Neoplasm recurrence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Recurrent cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Partial seizures with secondary generalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Laryngeal dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Respiratory tract oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Tracheal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="407" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="335" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="206"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="206"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was stopped prematurely due to futility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

